For instance, current evidence suggests that the therapeutic application of miR-181b may limit the release of CXCL1 from the vascular endothelium and thereby reducing atherosclerosis, whereas the endothelial delivery of miR-126-3p boosts atheropotective CXCL12 expression. The gene discussed is CXCL1; the disease is atherosclerosis.